FTC Will Investigate Anti-Competitive Rebating But Any Enforcement Action Would Take Time

Commission policy statement highlights situations where rebates lead to formulary exclusion of lower-priced insulin. But concern is also relevant for other drug classes, including highly-anticipated coverage decisions for biosimilars to Humira.